TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05245474

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)
Description: Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)
Description: Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
Study: NCT05607147

Intervention type: DEVICE
Group type: OTHER
Intervention: Testing for SARS CoV2 Antigen and Antibody
Description: Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
Study: NCT05845983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Description: Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
Study: NCT04811482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCIT-CALM (Teacher-Child Interaction Training-CALM)
Description: This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
Study: NCT04965532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane anesthesia
Description: Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane anesthesia
Description: Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
Study: NCT04886791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal NOTES hysterectomy
Description: Vaginal assited NOTES hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy
Description: Vaginal hysterectomy
Study: NCT05018663

Intervention type: OTHER
Intervention: Artificial Intelligence software ROSE
Description: Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
Study: NCT06131138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercises
Description: This include aquatic exercises thrice as week for 6 weeks.
Study: NCT05298709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperventilation and CO2 challenge
Description: Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators as described in study arm.
Study: NCT05545189

Intervention type: DIAGNOSTIC_TEST
Intervention: colonoscopy,polypectomy
Description: polyp removal during colonoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: colonoscopy,polypectomy
Description: polyp removal during colonoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: colonoscopy,polypectomy
Description: polyp removal during colonoscopy
Study: NCT05053035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL001
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via intravenous (IV) infusion
Study: NCT05762276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXX-401
Description: A synthetic PCSK9 peptide-based immunotherapy
Study: NCT05929183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial magnetic stimulation
Description: Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of depressive symptom was dorsolateral prefrontal cortex (DLPFC). In this study, we use high frequency rTMS in the occipital lobe are precisely targeted by navigation, by stimulating the primary visual cortex（V1), can affect the orbitofrontal cortex (OFC), which is functionally connected to V1, and thus affect the entire nerve ring pathway excitability, thereby rapidly, effectively and safely improving mood symptoms in the acute phase of bipolar depressive episode.~After the target was determined by fMRI navigation and positioning, the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial magnetic stimulation
Description: The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters were the same as the Active Comparator arm.
Study: NCT05762276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXX-401
Description: A synthetic PCSK9 peptide-based immunotherapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT05667233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training Program
Description: Participants will undergo a high exertion machine-based resistance training protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training Program
Description: Participants will undergo a high exertion machine-based resistance training protocol.
Study: NCT05796076

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual reality
Description: Participants in the intervention group will be received VR during the suturing procedure. Virtual reality is a three dimensions of width, height and depth that is generated digitally in a computer-generated environment that allows a user to interact with it 16.
Study: NCT05094934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 100 mg
Description: All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 100 mg
Description: All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC0385-0434 A 100 mg
Description: All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
Study: NCT06416540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband Exercises plus Conventional Physiotherapy and Rehabilitation Program
Description: Upper extremity, shoulder flexion, abduction, elbow flexion and wrist extension movements will be applied to the study group by the physiotherapist in combination with the breathing pattern. The program will start with yellow therabant and the difficulty level will be increased according to the patient's condition. Exercise training will be applied in a total of 3 sets, 30-60 min/session, 5 days/week, 8-10 repetitions/set, depending on the condition of each patient, during the patients' stay in the intensive care unit.~Conventional Physiotherapy and Rehabilitation Program Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physiotherapy and Rehabilitation Program
Description: Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient.
Study: NCT05094934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 100 mg
Description: All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
Study: NCT06416540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy and Rehabilitation Program
Description: Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient.
Study: NCT06415825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard advice and Preliminary muscle contraction
Description: The maneuver groups will receive standard advice and an additional one - preliminary contraction of the muscles in the corresponding kinesiology segment. This advice will be embedded in all motor activities of daily living involving the relevant area.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard advice
Description: Standard advice includes avoiding heavy physical activity, sudden and unexpected loads, repetitive and prolonged overloads, and long periods of hypomobility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard advice
Description: Standard advice includes avoiding heavy physical activity, sudden and unexpected loads, repetitive and prolonged overloads, and long periods of hypomobility.
Study: NCT05860894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable ECG holter device (Biomonitor3, Biotronik)
Description: Subcutaneous implantation of ECG holder device to monitor ECG
Study: NCT05603949

Intervention type: DEVICE
Intervention: 3D deep learning neural network system
Description: With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
Study: NCT05910788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal cannula
Description: The purpose of this intervention is clarify the benefit with the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.~is to clarify whether there is benefit from the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.
Study: NCT05329142

Intervention type: DIAGNOSTIC_TEST
Intervention: Surplus sample toxicology analysis
Description: Anonymised surplus blood sample will be analysed for drugs and their metabolites by way of Mass Spectrometry and LGC Group, Cambridge.
Study: NCT05253066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with exemestane (+/- goserelin)
Description: Chidamide combined with exemestane (+/- goserelin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
Description: Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
Study: NCT06208436

Intervention type: OTHER
Intervention: Adjuvant chemotherapy
Description: Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone
Study: NCT05461846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated neuromuscular inhibition technique
Description: is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
Study: NCT04586127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AYA NA-SB Questionnaire
Description: Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
Study: NCT06380985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized VR Alcohol Approach Bias Modification (ApBM) Condition
Description: The Personalized VR ApBM will consist of 2D pictures representing alcohol or positive images (e.g., representing family or friends enjoying time together; sports, pets; travel and holidays, etc.) presented in a unique format in VR (e.g., landscape/portrait orientation), which will serve as the cue requiring a stimulus response. Participants are instructed to push the images away from them if they are presented in one format (e.g., landscape) and grab (using lever on VR controller) the images and pull towards themselves in response to a separate format (e.g., portrait pictures) across a virtual table. Each training session starts with 10 practice trials showing neutral objects (containers), followed by 240 training trials (120 alcohol and 120 non-alcohol trials). Training effect is achieved by altering the contingency of push vs. pull by image type (alcohol vs. positive).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Condition
Description: Sham training is identical to ApBM, except the contingency of each orientation (e.g., portrait or landscape) representing a push vs. a pull is altered to diminish training effect.
Study: NCT05311631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Description: The core of the intervention is a trustful relation between the health visitor and the families based on principles of needs based communication. Health visitors will enhance parents' action competence based on breastfeeding self-efficacy, focusing on parents' wishes and needs.~The breastfeeding support includes four main messages: joint parenting task, skin-to-skin contact, frequent breastfeeding, and good positioning.~Training of health visitors includes e-learning and a two-day course with physical attendance. Supportive materials are developed including communicative support tools and a web-page providing support and knowledge when the health visitor is off hours.~All families in intervention sites accepting the health visitor program will receive the improved breastfeeding support. Families in the high-risk group are offered an intensified intervention with close follow-up by telephone in planned time-intervals, thus a higher dose of the intervention.
Study: NCT05991791

Intervention type: OTHER
Group type: OTHER
Intervention: Early Start Denver Model (ESDM)
Description: Phase A~* 4 individual sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~Phase B :~* 11 sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM with the help of the robot Pepper~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~Phase C :~* 4 sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM without the help of the robot Pepper~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~* All sessions will also be filmed and recorded
Study: NCT06048276

Intervention type: DRUG
Intervention: Herbal medicines (e.g., Yunkang granules, Duzhong granules)
Description: Herbal medicines (e.g., Yunkang granules, Duzhong granules) exposure at the early gestation.
Study: NCT05616793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV8.hLCA5
Description: Adeno-associated virus vector expressing human LCA5 gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV8.hLCA5
Description: Adeno-associated virus vector expressing human LCA5 gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV8.hLCA5
Description: Adeno-associated virus vector expressing human LCA5 gene
Study: NCT05228678

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise tests
Description: Spirometry~* forced expiratory volume in 1 second (FEV1) % predicted,~* forced vital capacity (FVC)% predicted,~* forced expiratory volume in 1 second /forced vital capacity FEV1 /FVC

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise tests
Description: Spirometry~* forced expiratory volume in 1 second (FEV1) % predicted,~* forced vital capacity (FVC)% predicted,~* forced expiratory volume in 1 second /forced vital capacity FEV1 /FVC
Study: NCT05894837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab+Regorafenib
Description: Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Bicarbonate Infusion
Description: hepatic artery bicarbonate infusion: once every four weeks
Study: NCT05117346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARDIX-101A, CARDIX-101B, CARDIX-101C
Description: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.
Study: NCT06291194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-S56 5%
Description: After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group(Vehicle)
Description: After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
Study: NCT06550609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine Oral Capsule
Description: Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
Study: NCT06243276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One stage implant surgery
Description: It is a technique in which the healing cap is connected to the implant at the stage of implant placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One stage implant surgery
Description: It is a technique in which the healing cap is connected to the implant at the stage of implant placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two stage implant surgery
Description: It is a technique in which the healing cap is connected to the implant three months after the implant is placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two stage implant surgery
Description: It is a technique in which the healing cap is connected to the implant three months after the implant is placed.
Study: NCT06361927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody
Study: NCT00012922

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Literacy Intervention for Colorectal Cancer Screening
Study: NCT06560411

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Ventilation
Description: Provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation
Study: NCT06299787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: Theta-burst stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Stimulation with double-sided B70-type coil
Study: NCT05786911

Intervention type: OTHER
Intervention: nutritional score
Description: correlation between a food habit and nutritional status score of the parturient and a postpartum fatigue (FSS) and pain (ENA) score
Study: NCT06131138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core strengthening
Description: This include core strengthening exercises thrice a week for 6 weeks